INNO-LIPA® HBV Multi-DR
Minimize treatment failure, Maximize long-term HBV suppression
Line probe assay for simultaneous detection of hepatitis B virus wild-type motif, lamivudine, telbivudine, emtricitabine, adefovir, and entecavir resistance-associated mutations.
Product number 81382
Click here to navigate
- Contact sales for information
- Details
- Conditions of sale
- Citations
- Documentation
- Insights
- Product inquiry
- Related products
-
Details
Features & Benefits
- Earliest detection of mutants:
- Highly sensitive detection at single nucleotide level of mixtures of wild-type and mutants, identifying the appearance of mutants earlier than sequencing and viral load assays
- Lower limit of detection of 990 copies/ml
- Allowing rapid and effective HBV suppression by early adoption to the most suited therapy
- All the necessary information in one assay:
- Allows simultaneous detection of all clinically relevant HBV polymerase wild-type and drug-induced mutations associated with lamivudine, emtricitabine, telbivudine, adefovir and tenofovir resistance as well as known compensatory mutations (codons 80, 173, 180, 181, and 204)
- Identifies amino acid changes in the overlapping reading frame of HBsAg (codons 171, 172, 195, 196, 198, and 199)
- Optimized for 8 known HBV genotypes (A-H)
- Low chance of errors and limited hands-on time:
- Easy to perform and robust assay
- Amplicon can also be used for INNO-LIPA HBV GT
- Fully automated processing of the strips possible with Auto-LIPA™ 48 and AutoBlot 3000H.
- Objective and automated reading and interpretation of strips possible using LiRAS® for Infectious Diseases.
-
Conditions of sale
To read the end user conditions of sale for this product please visit our Resource center.
-
Citations
The BIOZ badges associated with Fujirebio products include peer-reviewed citations derived from scientific studies using Fujirebio products. Please note that the peer-reviewed citations do not reflect the regulatory status of Fujirebio products. Users should refer to the specific product documentation and any (clinical) claims made therein in order to ensure compliant use. For each country or geographic region, users must verify the related regulatory status of the Fujirebio product.
-
Documentation
Browse regulatory documents for this product
Create a (free!) eServices account and start browsing all product documentation right away.
Get access to this section and more
Create a free eServices account now and instantly access multiple digital resources:
- Product documentation
- Selected scientific posters
- Product leaflets
- How-to videos and more…
Multimedia
Watch product videos
Get a (free!) eServices account and benefit from full access to all our online resources.
-
Insights
Jul 10, 2019HBcrAg, a promising new serological marker for reliable and non-invasive monitoring of the intrahepatic virologic status in HBV patients
In March 2017 the European Association for the Study of the Liver (EASL) added a new serological marker, HBcrAg (Hepatitis B core-related antigen), to...
-
Product inquiry
-
Related products